曹 宇      
  • 教育背景及工作经历

     

    2022-至今         深圳湾实验室,专项研究员
    2017-至今         北京大学深圳研究生院,课题组长,特聘研究员
    2016-2017        美国索伦托医疗制药,资深科学家
    2013-2016        斯克里普斯研究所(导师:Peter G. Schultz), 助理研究员
    2007-2013        MD Anderson癌症研究中心(导师: Michael G. Rosenblum), 博士后
    2001-2007        南开大学(导师:白钢),理学博士
    1996-2000        辽宁大学, 理学学士
  • 研究兴趣

           

           近年来,癌症免疫治疗备受关注,是癌症治疗领域的焦点。2011年12月,Nature及临床肿瘤最顶级杂志Journal of Clinical Oncology分别发表相同题目《癌症免疫治疗的时代已经来临》的评论文章,预测免疫细胞治疗将对肿瘤治疗带来的重大影响。本课题组通过严格考察不同免疫治疗药物的独特抗肿瘤机理和潜在毒副作用,旨在设计和开发用于个性化治疗的精准药物策略。通过找到用于靶向不同血液肿瘤和实体肿瘤的最佳设计方案,本课题组将开发新型药物开发设计平台,并且制备新型的个性化抗肿瘤免疫治疗药物。

  • 代表性成果(近5年)                                  

     

    1.Lijun Zhao, Shuhong Li, Xiaoyi Wei, Xuexiu Qi, Qiaoru Guo, Licai Shi, Ji-Shuai Zhang, Jun Li, Ze-Lin Liu, Zhi Guo, Hongyu Zhang, Jia Feng, Yuanyuan Shi, Suping Zhang, Yu J. Cao*, A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignances, Protein & Cell, 2024, Jun 1; Online ahead of print. PMID: 38823002.

    2.Qiao-ru Guo, Yu J. Cao*, Applications of genetic code expansion technology in eukaryotes, Protein & Cell, 2024 May 7;15(5):331-363. PMID: 37847216.

    3.Dong Liu, Xuexiu Qi, Xiaoyi Wei, Lijun Zhao, Xuechun Wang, Shuhong Li, Zhidong Wang, Lisai Shi, Jie-an Xu, Mei Hong, Zhong Liu, Lili Zhao*, Xiankun Wang, Bo Zhang, Yuhan Zhang, Feng Wang, Yu J. Cao*, A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy, Theranostics, 2022, Nov 14;12(18):7788-7803. PMID: 36451856.

    4.Lijun Zhao, Shuhong Li, Xiaoyi Wei, Xuexiu Qi, Dong Liu, Lei Liu, Feiqiu Wen, Ji-shuai Zhang, Feng Wang, Ze-lin Liu*, Yu J. Cao*, A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL, Blood, 2022 Oct 20; 140(16): 1790-1802. PMID: 35981465.

    5.Yu J. Cao*,, Chenfei Yu, Kuan-Lin Wu, Xuechun Wang, Dong Liu, Zeru Tian, Lijun Zhao, Xuexiu Qi, Axel Loredo, Anna Chung, Han Xiao*. Synthesis of precision antibody conjugates using proximity-induced chemistry, Theranostics, 2021, Aug 27; 11(18):9107-9117. PMID: 34522229.

    6.Yu J. Cao*, Xuechun Wang, Zhidong Wang, Lijun Zhao, Shuhong Li, Zhuxia Zhang, Xiaoyi Wei, Hwayoung Yun, Sei-hyun Choi, Zhong Liu, Lili Zhao, Stephanie A. Kazane. Switchable CAR-T Cells Outperformed Traditional Antibody-Redirected Therapeutics Targeting Breast Cancers, ACS Synthetic Biology, 2021, May 21; 10(5):1176-1183. PMID: 33856201 (Research Highlight in Nature Chemical Biology).

    7.Zhidong Wang, Yu J. Cao*. Adoptive cell therapy targeting neoantigens: a frontier for cancer research, Frontiers in Immunology, 2020, Mar 5; 11: 176-188. PMID: 32194541.

    8.Lijun Zhao, Yu J. Cao*. Engineered T Cell Therapy for Cancer in the Clinic, Frontiers in Immunology, 2019, Oct 11; 10: 2250-2269. PMID: 31681259.

    9.Yuhan Zhang, Changming Fang, Rongsheng E. Wang, Ying Wang, Hui Guo, Chao Guo, Lijun Zhao, Shuhong Li, Xia Li, Peter G. Schultz*, Yu J. Cao*, Feng Wang*. A tumor-targeted immune checkpoint blocker, Proceedings of the National Academy of Sciences, 2019, Aug 6; 116(32):15889-15894. PMID: 31332018.

    10.Lawrence H. Cheung, Yunli Zhao, Ana Alvarez-Cienfuegos, Khalid A. Mohamedali, Yu J. Cao, Walter N. Hittelman, Michael G. Rosenblum. Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B, Journal of Experimental & Clinical Cancer Research, 2019, Jul 30; 38(1): 332-345. PMID: 31362764.

 

职务 课题组长,特聘研究员 电话 +86-755-2603-3107
邮箱 joshuacao@pku.edu.cn